Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Functional genomics study on Non Alcoholic fatty liver disease (NAFLD) (Study ST000678)

C18 NEGATIVE ION MODE (Analysis AN001042)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
PG 44:12; [M-H]-@4.64	ME188277	0.21	0.81	0.58	2.43	1.07	0.89
plasmenyl-PE 34:2; [M-H]-@6.70	ME188305	0.45	1.11	0.59	1.35	1.20	1.31
PG 42:10; [M-H]-@4.78	ME188271	0.23	0.89	0.90	1.38	1.63	0.96
PG 38:7; [M-H]-@4.56	ME188265	0.30	1.01	0.69	1.28	1.54	1.18
PG 40:8; [M-H]-@4.80	ME188270	0.28	0.89	0.81	1.22	1.68	1.13
PG 34:1; [M-H]-@5.86	ME188252	0.27	0.86	0.98	1.54	1.29	1.06
PG 40:7; [M-H]-@5.18	ME188269	0.26	0.97	1.00	1.40	1.29	1.07
PG 44:10; [M-H]-@5.45	ME188275	0.24	1.01	0.97	1.23	1.41	1.14
PS 36:1; [M-H]-@6.55	ME188288	0.40	1.03	1.03	1.14	1.25	1.16
CL 70:3; [M-2H](2-)@9.68	ME188130	0.76	1.07	0.92	1.36	0.87	1.03
plasmenyl-PE 36:5; [M-H]-@6.29	ME188309	0.52	1.02	1.10	1.48	1.02	0.87
CL 72:4; [M-2H](2-)@9.71	ME188133	0.33	1.17	0.95	1.86	0.78	0.90
PG 44:11; [M-H]-@5.04	ME188276	0.26	0.80	0.99	1.97	0.96	1.03
FFA(20:2)	ME188142	0.50	1.33	1.50	0.59	0.77	1.31
FFA(18:1)	ME188138	0.66	1.10	1.59	0.68	0.70	1.26
FFA(24:1)	ME188149	0.85	1.06	1.46	0.69	0.71	1.24
FFA(20:1)	ME188141	0.64	1.00	1.48	0.86	0.51	1.50
FFA(22:2)	ME188146	0.66	1.05	1.49	0.82	0.53	1.46
FFA(24:2)	ME188150	0.66	0.98	1.67	0.96	0.55	1.18
FFA(22:3)	ME188147	0.68	1.01	1.71	0.73	0.49	1.39
FFA(24:3)	ME188151	0.69	1.01	1.78	0.66	0.56	1.30
PG 42:8; [M-H]-@5.40	ME188273	0.46	1.24	1.02	1.11	1.04	1.14
PE 32:0; [M-H]-@6.73	ME188221	0.65	1.25	1.24	0.83	0.95	1.09
PG 36:3; [M-H]-@5.37	ME188258	0.56	1.27	1.07	0.83	1.07	1.20
plasmenyl-PE 38:1; [M-H]-@8.17	ME188310	0.48	1.00	1.31	0.72	1.12	1.36
FFA(22:1)	ME188145	0.46	1.04	1.57	0.72	0.93	1.27
CL 72:5; [M-2H](2-)@9.56	ME188134	0.43	0.97	1.52	0.74	1.18	1.17
FFA(24:0)	ME188148	0.52	1.08	1.49	0.63	1.13	1.15
PG 36:2; [M-H]-@5.94	ME188257	0.29	0.89	1.44	0.97	1.36	1.05
PG 40:6; [M-H]-@5.56	ME188268	0.38	0.88	1.25	1.03	1.31	1.16
plasmenyl-PE 36:4; [M-H]-@6.65	ME188308	0.58	0.90	1.16	1.16	1.08	1.11
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.44	ME188155	0.70	0.94	1.27	0.97	1.05	1.06
PI 40:5; [M-H]-@6.07	ME188284	0.57	0.91	1.21	0.97	1.08	1.26
plasmenyl-PE 38:5; [M-H]-@6.74	ME188313	0.59	0.92	1.36	0.87	1.02	1.24
FFA(20:4) Arachidonic acid	ME188143	1.03	1.06	1.09	1.25	0.42	1.14
plasmenyl-PE 36:2; [M-H]-@7.28	ME188307	0.90	0.97	0.73	1.25	0.61	1.54
FFA(18:2)	ME188139	0.97	1.23	1.16	0.55	0.48	1.60
PE 30:0; [M-H]-@6.04	ME188219	1.18	1.02	1.23	0.57	0.74	1.26
plasmenyl-PE 36:1; [M-H]-@7.69	ME188306	0.53	0.95	1.12	0.90	0.82	1.67
plasmenyl-PE 40:5; [M-H]-@7.48	ME188315	1.16	0.78	1.04	0.80	0.74	1.48
plasmenyl-PE 32:1; [M-H]-@6.60	ME188303	0.75	0.96	1.10	0.89	0.90	1.40
plasmenyl-PE 40:6; [M-H]-@7.19	ME188316	0.96	0.92	0.98	0.80	0.82	1.52
FFA(22:0)	ME188144	0.80	0.97	0.89	0.86	0.92	1.57
FFA(16:0)	ME188136	0.89	0.91	0.89	0.84	0.82	1.64
FFA(18:0)	ME188137	0.92	0.97	0.90	0.81	0.83	1.57
FFA(20:0)	ME188140	0.87	1.00	0.84	0.85	0.83	1.60
PC 42:4; [M-Ac-H]-@7.66	ME188210	0.98	0.97	0.76	0.71	1.22	1.36
plasmenyl-PE 38:2; [M-H]-@7.86	ME188311	1.07	1.04	0.62	0.81	1.09	1.37
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.46	ME188152	0.91	1.10	0.99	0.84	0.92	1.23
PC 42:9; [M-Ac-H]-@6.11	ME188214	0.99	1.13	0.81	0.79	1.10	1.18
PC 30:2; [M-Ac-H]-@4.92	ME188163	1.08	1.16	0.63	0.39	0.95	1.79
PC 32:2; [M-Ac-H]-@5.57	ME188167	0.98	1.15	0.73	0.55	1.04	1.55
N-(hexadecanoyl)-sphinganine; [M-H]-@7.07	ME188154	0.96	1.14	0.84	0.54	1.10	1.42
PE 32:1; [M-H]-@6.21	ME188222	0.98	1.21	0.83	0.45	1.16	1.38
PC 26:0; [M-Ac-H]-@4.44	ME188157	0.77	1.24	0.74	0.54	1.00	1.72
PC 36:6; [M-Ac-H]-@5.35	ME188184	0.78	1.16	0.88	0.63	1.01	1.54
PE 35:3; [M-H]-@6.24	ME188230	1.15	1.18	0.71	0.43	1.74	0.80
lysoPE 20:3; [M-H]-@1.72	ME188300	1.33	1.15	0.45	0.58	1.43	1.06
PC 40:0; [M-Ac-H]-@8.66	ME188200	1.07	0.97	0.70	0.80	1.47	0.99
PS 40:6; [M-H]-@6.00	ME188295	0.27	0.69	1.00	0.20	1.84	2.00
PI 38:5; [M-H]-@5.46	ME188283	0.27	1.00	1.21	0.58	1.13	1.81
PI 36:2; [M-H]-@5.95	ME188278	0.23	0.88	1.09	0.56	1.59	1.65
PI 38:4; [M-H]-@5.93	ME188282	0.20	0.70	1.19	0.56	1.55	1.80
PC 28:1; [M-Ac-H]-@4.69	ME188159	0.61	1.54	0.57	0.60	1.35	1.33
PG 32:1; [M-H]-@5.31	ME188251	0.42	1.23	0.64	1.02	1.17	1.51
plasmenyl-PE 34:1; [M-H]-@7.16	ME188304	0.45	1.03	0.67	0.87	1.42	1.57
PS 38:5; [M-H]-@5.61	ME188292	0.55	0.89	0.73	0.72	1.20	1.92
PS 32:1; [M-H]-@5.25	ME188285	0.30	1.03	0.75	0.71	1.34	1.88
PS 34:2; [M-H]-@5.34	ME188287	0.43	1.20	0.80	0.61	1.24	1.71
PE 31:1; [M-H]-@5.94	ME188220	0.65	1.03	0.89	0.26	1.91	1.26
PC 37:3; [M-Ac-H]-@6.78	ME188187	0.54	0.89	0.66	0.44	2.30	1.16
PE 35:4; [M-H]-@6.00	ME188231	0.53	0.96	0.74	0.28	2.29	1.20
PC 39:3; [M-Ac-H]-@7.39	ME188198	0.41	0.85	0.92	0.39	2.16	1.27
PE 39:2; [M-H]-@7.70	ME188239	0.46	0.87	0.85	0.36	2.00	1.46
PS 39:3; [M-H]-@6.70	ME188293	0.48	0.75	0.86	0.52	1.98	1.40
PC 39:2; [M-Ac-H]-@7.57	ME188197	0.39	0.92	0.82	0.67	2.03	1.17
PC 38:3; [M-Ac-H]-@7.01	ME188193	0.55	0.99	0.72	0.46	2.00	1.27
PE 37:4; [M-H]-@6.64	ME188236	0.54	1.01	0.80	0.53	1.92	1.20
PC 35:3; [M-Ac-H]-@6.12	ME188179	0.47	1.02	0.73	0.42	2.15	1.22
PE 39:4; [M-H]-@7.13	ME188240	0.48	0.90	0.78	0.48	2.09	1.26
PS 38:3; [M-H]-@6.40	ME188290	0.29	0.88	0.60	0.38	2.31	1.53
PS 38:4; [M-H]-@6.02	ME188291	0.19	0.71	0.52	0.48	2.34	1.75
PI 36:3; [M-H]-@5.78	ME188279	0.21	0.77	0.89	0.33	2.05	1.74
PI 36:4; [M-H]-@5.37	ME188280	0.22	0.92	0.96	0.48	1.88	1.54
PI 38:3; [M-H]-@6.35	ME188281	0.15	0.88	0.81	0.46	2.20	1.50
PS 40:4; [M-H]-@6.49	ME188294	0.24	0.82	0.92	0.45	2.08	1.49
PG 38:5; [M-H]-@5.32	ME188263	0.26	1.07	1.26	0.72	1.77	0.92
PG 35:2; [M-H]-@5.51	ME188255	0.26	0.93	1.31	0.65	1.81	1.05
PG 40:5; [M-H]-@5.94	ME188267	0.33	0.87	1.29	0.63	1.89	0.99
PG 38:4; [M-H]-@6.06	ME188262	0.36	0.90	1.43	0.64	1.61	1.07
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.82	ME188153	0.46	0.81	1.26	0.71	1.67	1.09
PC 37:6; [M-Ac-H]-@5.66	ME188190	0.36	0.83	1.21	0.64	1.81	1.16
PG 36:1; [M-H]-@6.58	ME188256	0.25	1.06	1.04	0.87	1.53	1.26
PG 38:3; [M-H]-@5.91	ME188261	0.29	0.94	1.15	0.81	1.77	1.05
PG 42:9; [M-H]-@5.05	ME188274	0.27	0.93	1.17	0.89	1.63	1.12
PG 38:2; [M-H]-@6.31	ME188260	0.26	0.82	1.03	1.04	1.69	1.15
PG 38:6; [M-H]-@5.02	ME188264	0.23	0.95	0.96	0.92	1.75	1.19
CL 70:4; [M-2H](2-)@9.49	ME188131	0.62	0.90	1.04	0.81	1.21	1.42
PC 42:7; [M-Ac-H]-@6.75	ME188213	0.79	0.83	0.92	0.66	1.29	1.51
PC 28:0; [M-Ac-H]-@5.19	ME188158	0.64	1.30	0.92	0.60	1.19	1.35
PA 34:1; [M-H]-@5.79	ME188156	0.60	1.17	1.00	0.52	1.38	1.32
PC 40:7; [M-Ac-H]-@6.18	ME188207	0.42	1.09	1.11	0.66	1.29	1.42
plasmenyl-PE 42:5; [M-H]-@7.95	ME188317	0.44	1.11	1.07	0.67	1.33	1.38
PC 29:0; [M-Ac-H]-@5.47	ME188160	0.58	1.06	1.12	0.54	1.30	1.41
plasmenyl-PE 40:4; [M-H]-@7.78	ME188314	0.60	1.06	1.05	0.57	1.26	1.45
PC 31:1; [M-Ac-H]-@5.63	ME188165	0.70	1.21	1.12	0.45	1.00	1.53
PE 33:0; [M-H]-@6.89	ME188223	0.72	1.08	1.15	0.48	1.09	1.48
plasmenyl-PE 42:6; [M-H]-@7.72	ME188318	0.70	1.09	1.12	0.57	1.12	1.41
PC 37:5; [M-Ac-H]-@6.00	ME188189	0.80	0.92	1.11	0.56	1.27	1.33
PE 35:1; [M-H]-@7.04	ME188229	0.92	0.98	1.14	0.59	1.08	1.28
PC 44:2; [M-Ac-H]-@8.74	ME188216	0.87	1.05	0.84	0.68	1.40	1.16
PC 44:3; [M-Ac-H]-@8.39	ME188217	0.90	0.95	0.74	0.71	1.42	1.30
PC 30:0; [M-Ac-H]-@5.88	ME188161	0.63	1.13	0.97	0.79	1.20	1.28
PC 34:1; [M-Ac-H]-@6.59	ME188172	0.59	1.11	0.98	0.78	1.37	1.17
PE 36:0; [M-H]-@7.82	ME188232	0.61	1.09	0.88	0.80	1.35	1.26
PG 36:4; [M-H]-@5.10	ME188259	0.58	1.09	0.94	0.75	1.36	1.27
lysoPE 18:1; [M-H]-@1.82	ME188299	0.55	1.01	0.95	0.73	1.53	1.24
PC 38:5; [M-Ac-H]-@6.30	ME188195	0.53	1.06	0.90	0.79	1.50	1.22
lysoPE 18:0; [M-H]-@2.46	ME188298	0.67	1.08	0.81	0.70	1.47	1.27
lysoPE 20:4; [M-H]-@1.31	ME188301	0.72	1.08	0.79	0.76	1.40	1.25
PG 39:6; [M-H]-@5.30	ME188266	0.67	0.82	1.14	0.89	1.48	1.00
PE 43:4; [M-H]-@8.31	ME188249	0.74	1.07	1.30	0.67	1.18	1.04
PE 40:1; [M-H]-@8.37	ME188242	0.70	1.00	1.16	0.82	1.22	1.10
CL 70:5; [M-2H](2-)@9.31	ME188132	0.72	1.00	1.18	0.70	1.20	1.20
PE 34:1; [M-H]-@6.84	ME188225	0.63	1.02	1.16	0.72	1.25	1.22
PG 42:7; [M-H]-@5.78	ME188272	0.51	0.97	1.13	0.89	1.37	1.14
PC 40:2; [M-Ac-H]-@7.83	ME188202	0.54	0.91	1.16	0.72	1.43	1.25
PE 40:6; [M-H]-@6.74	ME188245	0.52	1.08	1.16	0.65	1.40	1.19
PC 37:4; [M-Ac-H]-@6.44	ME188188	0.79	0.90	0.76	0.50	1.79	1.27
PC 44:1; [M-Ac-H]-@9.15	ME188215	0.95	0.85	0.79	0.49	1.65	1.27
CL 68:3; [M-2H](2-)@9.44	ME188128	0.79	0.95	0.95	0.52	1.40	1.39
PC 37:1; [M-Ac-H]-@7.41	ME188185	0.73	0.95	0.98	0.48	1.50	1.37
CL 68:4; [M-2H](2-)@9.26	ME188129	0.78	0.88	0.89	0.48	1.51	1.45
PE 35:0; [M-H]-@7.46	ME188228	0.79	0.87	0.84	0.43	1.50	1.56
CL 66:4; [M-2H](2-)@9.01	ME188127	0.73	1.14	0.86	0.35	1.54	1.38
PC 34:4; [M-Ac-H]-@5.50	ME188175	0.93	1.14	0.79	0.42	1.47	1.24
PE 42:4; [M-H]-@8.00	ME188247	0.51	1.14	1.08	0.55	1.56	1.17
lysoPE 22:6; [M-H]-@1.29	ME188302	0.62	1.05	1.07	0.56	1.60	1.11
PC 42:6; [M-Ac-H]-@7.14	ME188212	0.56	0.96	1.04	0.61	1.67	1.17
PE 39:6; [M-H]-@6.60	ME188241	0.53	0.93	1.10	0.44	1.67	1.33
PC 35:1; [M-Ac-H]-@6.88	ME188177	0.48	0.88	1.16	0.54	1.68	1.26
PC 37:2; [M-Ac-H]-@7.06	ME188186	0.49	0.91	1.12	0.49	1.72	1.27
PC 31:0; [M-Ac-H]-@6.14	ME188164	0.49	0.97	1.15	0.57	1.49	1.33
PE 37:1; [M-H]-@7.57	ME188235	0.54	0.97	1.13	0.45	1.54	1.37
PE 42:8; [M-H]-@6.59	ME188248	0.56	1.05	1.07	0.50	1.50	1.32
PC 33:1; [M-Ac-H]-@6.30	ME188170	0.44	1.04	1.03	0.43	1.77	1.28
PE 40:4; [M-H]-@7.49	ME188244	0.50	1.07	0.86	0.53	1.68	1.36
PE 44:2; [M-H]-@8.79	ME188250	0.47	1.15	0.92	0.54	1.71	1.21
PE 33:1; [M-H]-@6.48	ME188224	0.51	1.08	0.97	0.47	1.71	1.26
PE 37:5; [M-H]-@6.17	ME188237	0.55	1.12	0.90	0.46	1.74	1.23
PC 33:0; [M-Ac-H]-@6.73	ME188169	0.50	0.91	0.92	0.59	1.84	1.22
PC 35:0; [M-Ac-H]-@7.31	ME188176	0.42	0.94	0.98	0.62	1.84	1.19
PC 42:2; [M-Ac-H]-@8.30	ME188209	0.60	1.01	0.88	0.67	1.71	1.13
PC 35:2; [M-Ac-H]-@6.47	ME188178	0.61	1.04	0.85	0.59	1.78	1.13
PC 40:4; [M-Ac-H]-@7.17	ME188204	0.55	1.05	0.85	0.66	1.77	1.12
PC 42:5; [M-Ac-H]-@7.37	ME188211	0.52	1.05	1.06	0.59	1.75	1.03
PC 40:3; [M-Ac-H]-@7.48	ME188203	0.49	1.04	0.89	0.69	1.85	1.04
PC 35:4; [M-Ac-H]-@5.81	ME188180	0.43	1.00	1.05	0.66	1.82	1.05
PG 34:3; [M-H]-@4.76	ME188254	0.40	1.09	0.96	0.65	1.81	1.09
PE 41:4; [M-H]-@7.79	ME188246	0.50	0.93	0.98	0.35	1.70	1.54
PC 33:2; [M-Ac-H]-@5.93	ME188171	0.50	0.98	0.85	0.47	1.72	1.49
PE 40:3; [M-H]-@7.60	ME188243	0.43	1.01	0.85	0.43	1.70	1.57
PE 38:1; [M-H]-@7.87	ME188238	0.43	0.97	0.84	0.60	1.60	1.55
PS 34:1; [M-H]-@5.93	ME188286	0.32	0.95	0.92	0.51	1.70	1.61
PC 39:6; [M-Ac-H]-@6.30	ME188199	0.38	0.97	1.00	0.66	1.65	1.34
PS 36:4; [M-H]-@5.43	ME188289	0.33	0.90	1.01	0.73	1.61	1.43
PC 36:5; [M-Ac-H]-@5.66	ME188183	0.57	1.10	0.89	0.56	1.47	1.42
PC 40:6; [M-Ac-H]-@6.55	ME188206	0.46	1.00	0.92	0.64	1.57	1.42
plasmenyl-PE 38:4; [M-H]-@7.23	ME188312	0.51	1.00	0.95	0.67	1.46	1.40
PC 40:1; [M-Ac-H]-@8.22	ME188201	0.45	0.90	1.02	0.56	1.51	1.56
PS 40:7; [M-H]-@5.43	ME188296	0.39	1.11	0.97	0.46	1.51	1.56
PE 37:0; [M-H]-@7.95	ME188234	0.33	0.80	0.83	0.75	1.83	1.46
PC 40:5; [M-Ac-H]-@6.90	ME188205	0.49	1.00	0.72	0.64	1.79	1.35
PC 36:1; [M-Ac-H]-@7.16	ME188181	0.48	1.07	0.76	0.69	1.72	1.28
PC 38:2; [M-Ac-H]-@7.29	ME188192	0.46	0.98	0.83	0.71	1.73	1.28
lysoPE 16:0; [M-H]-@1.67	ME188297	0.40	1.05	0.77	0.58	1.76	1.44
PG 34:2; [M-H]-@5.28	ME188253	0.39	1.08	0.77	0.70	1.68	1.38
PC 38:1; [M-Ac-H]-@7.74	ME188191	0.47	0.87	0.75	0.63	1.83	1.44
PC 42:1; [M-Ac-H]-@8.71	ME188208	0.55	0.95	0.81	0.50	1.82	1.36
PC 38:4; [M-Ac-H]-@6.68	ME188194	0.64	1.02	0.67	0.67	1.83	1.16
PC 46:5; [M-Ac-H]-@8.32	ME188218	0.58	0.99	0.61	0.74	1.92	1.16
PC 34:3; [M-Ac-H]-@5.79	ME188174	0.71	1.13	0.73	0.49	1.79	1.15
PC 36:4; [M-Ac-H]-@6.07	ME188182	0.54	1.14	0.70	0.54	1.83	1.24
PE 36:3; [M-H]-@6.62	ME188233	0.59	1.20	0.72	0.51	1.77	1.21
PC 32:3; [M-Ac-H]-@5.27	ME188168	0.67	1.27	0.68	0.38	1.56	1.44
PE 34:3; [M-H]-@5.98	ME188226	0.66	1.30	0.74	0.29	1.71	1.30
PE 34:4; [M-H]-@5.65	ME188227	0.68	1.28	0.63	0.24	1.71	1.46
PC 30:1; [M-Ac-H]-@5.37	ME188162	0.58	1.29	0.80	0.54	1.43	1.36
PC 34:2; [M-Ac-H]-@6.18	ME188173	0.57	1.27	0.83	0.61	1.50	1.22
PC 38:7; [M-Ac-H]-@5.55	ME188196	0.47	1.20	0.76	0.53	1.58	1.45
CL 74:7; [M-2H](2-)@6.05	ME188135	0.48	1.27	0.69	0.59	1.72	1.25
PC 32:1; [M-Ac-H]-@6.00	ME188166	0.53	1.21	0.74	0.57	1.63	1.32

Factors:

F1	Construct:GCKR(P446L)
F2	Construct:GCKR(WT)
F3	Construct:NT
F4	Construct:PPP1R3B_2640
F5	Construct:PPP1R3B_3
F6	Construct:Vector

Data matrix